Patents by Inventor Christian Buning

Christian Buning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130123325
    Abstract: The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Barbel Fruhbeis, Joachim Tillner, Andreas Czich, Tobias Pahler
  • Publication number: 20130046004
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 26, 2011
    Publication date: February 21, 2013
    Applicant: SANOFI
    Inventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Bodo Scheiper, Klaus Wirth
  • Patent number: 8236810
    Abstract: The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Guenter Billen, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8163774
    Abstract: The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth DeFossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8138207
    Abstract: The present invention comprises the use of amino-carbonyl-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes, carbohydrate and lipid metabolic disorders and other blood sugar complications.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: March 20, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth DeFossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 8003668
    Abstract: The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: August 23, 2011
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7888343
    Abstract: The present invention involves substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are defined herein. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds and methods for the treatment of metabolic disorders such as type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerosis diseases and the like through the administration of said compositions.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: February 15, 2011
    Assignee: Sanofi-A Ventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7879864
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed which are inhibitors of the enzyme dipeptidyl peptidase IV (DDP-IV) and comprise novel substituted bicyclic 8-pyrrolidinoxanthines of formula I and their derivatives: wherein the various R-groups are defined herein. These compounds may be combined with other secondary active compounds which also are effective in the treatment of said disorders and the disease states or physiological manifestations arising therefrom.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: February 1, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7838528
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: November 23, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7795445
    Abstract: The present invention comprises the substituted 2-aminoalkylthiobenzimidazoles of formula I wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the treatment of type-2 diabetes.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: September 14, 2010
    Assignee: sanofi-aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7569700
    Abstract: The present invention relates to carboxamide derivative compounds of formula I in which R1-R6 and R12 are hereinafter defined and together comprise carboximide derivatives for the therapeutic treatment of diabetes, hyperglycemia, lipid and carbohydrate metabolism disorders, arteriosclerotic manifestations and disorders and other blood sugar related disorders through a metabolic blood sugar-lowering action.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: August 4, 2009
    Assignee: sanofi - aventis
    Inventors: Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
  • Publication number: 20070299090
    Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed which are inhibitors of the enzyme dipeptidyl peptidase IV (DDP-IV) and comprise novel substituted bicyclic 8-pyrrolidinoxanthines of formula I and their derivatives: wherein the various R-groups are defined herein. These compounds may be combined with other secondary active compounds which also are effective in the treatment of said disorders and the disease states or physiological manifestations arising therefrom.
    Type: Application
    Filed: February 13, 2007
    Publication date: December 27, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Christian Buning, Georg Tschank, Ulrich Werner
  • Publication number: 20070265284
    Abstract: The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc.
    Type: Application
    Filed: January 11, 2007
    Publication date: November 15, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Guenter Billen, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7094800
    Abstract: The invention relates to compounds of the formula I in which the radicals have the meanings stated in the text, their stereoisomeric forms, and their physiologically tolerated salts, physiologically functional derivatives and process for their preparation. The compounds are suitable for the treatment of disorders of metabolism, such as type 2 diabetes.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: August 22, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Holger Wagner, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Patent number: 7008957
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: March 7, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Holger Wagner, Karl Schoenafinger, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Publication number: 20050059716
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, their stereoisomeric forms and their physiologically tolerated salts and process for their preparation. The compounds are suitable for the treatment of metabohlic disorders such as type 2 diabetes.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Holger Wagner, Karl Schoenafinger, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner
  • Publication number: 20050059724
    Abstract: The invention relates to compounds of the formula I in which the radicals have the meanings stated in the text, their stereoisomeric forms, and their physiologically tolerated salts, physiologically functional derivatives and process for their preparation. The compounds are suitable for the treatment of disorders of metabolism, such as type 2 diabetes.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Karl Schoenafinger, Holger Wagner, Gerhard Jaehne, Holger Gaul, Christian Buning, Georg Tschank, Ulrich Werner